Sejal Kothadia
Rutgers University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sejal Kothadia.
Journal of Clinical Oncology | 2016
Sarah Lee; Zhen Wang; Sejal Kothadia; Yucai Wang; Ellen Olson; Yeun-Hee Anna Park; David Klein; F. Zhong; Victor Tsu-Shih Chang
75 Background: Liver cancer is a leading cause of death. Lack of data exists on palliative care in this group, and care varies by location. We aim to determine if there are differences in palliative care for patients (pts) with liver cancer by VA site. METHODS In an IRB approved protocol, we reviewed medical records of pts at 2 VA medical centers (S1, S2) with liver cancer, who were seen by Palliative Care between 2006 and 2012. Veterans were compared by 1) demographics: Karnofsky performance status > 50 (KPS), marital status, DNR/DNI, 2) palliative intervention: goals of care discussion, referrals to psychology and PT/OT, and 3) outcomes: ED visit within 1 month (mo) of death, ED visit within 6 mo of death, ICU within 30 days of death, and hospice as site of death, time from diagnosis to palliative care, and time from DNR to death. Chi-square, Fishers Exact, and T-test were performed with Stata. RESULTS here were 82 men, 30 from S1 and 52 from S2, median age 61 (35-87) and 63 (54-88) yrs, respectively. Pts were Caucasian 30 (36%), African American 47 (57%), and other 5 (0.1%). Cancer stages were locoregional 15 (50%), metastatic 13 (43%), and unknown 2 (0.1%) at S1 and 28 (54%), 20 (38%), 5 (0.1%) at S2. Differences were seen in KPS > 50: (S1, S2) [10 (33%), 15(29%) p = 0.010], married: (S1, S2) [7 (23%), 24(46%) p = 0.024], DNR/DNI: (S1, S2) [19 (63%), 13(25%), p = 0.001]. Regarding palliative intervention: goals of care discussion (S1, S2) [26 (87%), 44 (85%), p = 0.044], referral to psych (S1, S2) [16 (53%), 42 (81%) p = 0.014], referral to PT/OT (S1, S2) [17 (57%), 15 (29%), p = 0.007]. Finally in regards to outcome: ED visit within 1 mo of death (S1, S2) [7 (23%), 31 (60%), p = 0.001], ED visit within 6 mos of death (S1, S2) [18 (56%), 35 (67%) p = 0.031], ICU within 30 days of death (S1, S2) [0 (0%), 9 (17%) p = 0.019}, and hospice as site of death (S1, S2) [19 (63%), 21 (40%), p < .0001]. Other key differences included median number of days from diagnosis to initial palliative care consult (S1, S2) [97, 39, p = 0.001] and median number of days from DNR to death (S1, S2) [33, 14, p = 0.001]. CONCLUSIONS Results show there are site-specific differences between VA medical centers. These data may be important in the comparison of other centers and provide a baseline for future studies.
Journal of Clinical Oncology | 2016
Zhen Wang; Sarah Lee; Sejal Kothadia; Yucai Wang; Victor Tsu-Shih Chang; Yeun-Hee Anna Park; Ellen Olson; David Klein; F. Zhong
164 Background: Palliative care interventions and their effect on EOL outcomes for liver cancer pts have not been described. We investigated the association between palliative care intervention and EOL care outcomes. METHODS We reviewed the charts of pts with hepatocellular carcinoma and who were seen by palliative care at 2 VA medical centers from 2006 to 2012. We investigated the association between EOL outcomes (number of ER visits, ICU visits, chemotherapy, place of death, number of hospitalizations during their last 30 days), and interventions such as early referral (within 30 days of diagnosis), defined goals of care, holding a family meeting, and symptom assessment and management. The protocol was reviewed by the IRB of both VAs and analyses were done with SAS Studio v3.4. RESULTS 82 charts were reviewed (30 from EOVA and 52 from BVA). All Pts were men; 30 (39%) were white and 47(61%) African American. Interval from diagnosis to palliative care consult was 68 days (median). 72 (90%) pts were not aware of their diagnosis. 48 (65%) were not aware of prognosis. 65 (88%) had decision making capacity. 32 (39%) pts were DNR/DNI. 60 (86%) pts chose symptom management and 10 (14%) life prolongation. 47 pts (50%) had family meeting. In the last month, 35 pts (48%) had ER visit. 9 pts (12%) had ICU visits, 4 pts (5%) had chemotherapy and 48 pts (71%) had at least 1 hospitalization. 68 (85%) underwent symptom assessment. Most frequently treated symptoms were pain (78%), nausea (27%), constipation (46%), dyspnea (34%). Significant associations were found for early referral and ER admissions (OR = 3.2, p = 0.0178), family meeting and site of death (OR = 0.136 p = 0.0037), family meeting and number of hospitalizations (OR = 0.2652, p = 0.0169). Pts choosing symptom management and who had family meetings associated with hospice/home as place of death (chisq = 5.7368, p = 0.016). Knowledge of prognosis was not associated with site of death. CONCLUSIONS In this population, many palliative care interventions were performed. Early referral, family meetings were significantly associated with site of death, ER admissions, and number of hospitalizations. These results should be replicated in larger studies.
Journal of Clinical Oncology | 2016
Narjust Duma; Sejal Kothadia; Zhen Wang; Sarah Lee; Jesyree Veitia Campos; Bryant Van Leeuwen; Ramya Undamatla; Ricardo Daniel Parrondo; Komal Patel; Rima Panchal; Marshall McKenna; Veronica Mariotti; Jieqi Liu; Miguel Gonzalez Velez; Brittany Gladney; Larysa Sanchez; Shijia Zhang; Martin Gutierrez
Journal of Clinical Oncology | 2018
Giselle Alexandra Suero-Abreu; Miguel Gonzalez Velez; Marshall McKenna; Narjust Duma; Sejal Kothadia; Shalini R. Krishnasamy; Janice Liu; Ning Dong; Umar Sharif Khawaja; Daniel Pievsky; Tracy Ann Proverbs-Singh; Martin Gutierrez
Journal of Clinical Oncology | 2017
Sejal Kothadia; Zhen Wang; Sarah Lee; Victor Tsu-Shih Chang; Yeun-Hee Anna Park; Ellen Olson; David Klein; Andrea Nadine Leaf; Stephanie Hwa; F. Zhong
Journal of Clinical Oncology | 2017
Sejal Kothadia; Zhen Wang; Sarah Lee; Victor Tsu-Shih Chang; Yucai Wang; Yeun-Hee Anna Park; Ellen Olson; David Klein; Andrea Nadine Leaf; Stephanie Hwa; F. Zhong
Journal of Clinical Oncology | 2017
Narjust Duma; Yucai Wang; Miguel Gonzalez Velez; Sejal Kothadia; Veronica Mariotti; Ricardo Daniel Parrondo; Joleen M. Hubbard; Alex A. Adjei; Thorvardur R. Halfdanarson
Journal of Clinical Oncology | 2017
Miguel Gonzalez Velez; Narjust Duma; Valentina Jaramillo Restrepo; Pablo Lopez-Zertuche; Ricardo Daniel Parrondo; Veronica Mariotti; Sejal Kothadia; Beth Boseski; Andrew Jennis; Martin Gutierrez
Journal of Clinical Oncology | 2017
Miguel Gonzalez Velez; Narjust Duma; Valentina Jaramillo Restrepo; Pablo Lopez-Zertuche; Sejal Kothadia; Veronica Mariotti; Ricardo Daniel Parrondo; Beth Boseski; Andrew Jennis; Martin Gutierrez
European Journal of Cancer | 2017
Veronica Mariotti; M. Gonzalez Velez; Narjust Duma; Ricardo Daniel Parrondo; Sejal Kothadia; Brittany Gladney; Rima Panchal; Jieqi Liu; Komal Patel; Ramya Undamatla